Evidence map›Paper›PMID 40013140›Full record

ArticleFrontiers in immunology2025

Diethyldithiocarbamate-copper complex ignites the tumor microenvironment through NKG2D-NKG2DL axis.

Daciana C Dumut, Marian Hajduch, Amanda M Zacharias, Qingling Duan, Ivo Frydrych, Zuzana Rozankova, Miroslav Popper, Dusan Garic, Radu Alexandru Paun, Amanda Centorame and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daciana C DumutDepartment of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Marian HajduchInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Amanda M ZachariasDepartment of Biomedical & Molecular Sciences, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Qingling DuanDepartment of Biomedical & Molecular Sciences, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Ivo FrydrychInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Zuzana RozankovaInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Miroslav PopperInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Dusan GaricDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, United States.
Radu Alexandru PaunThe Research Institute of the McGill University Health Centre, Infectious Diseases in Global Health Program, Montreal, QC, Canada.
Amanda CentorameDepartment of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Juhi ShahThe Research Institute of the McGill University Health Centre, Infectious Diseases in Global Health Program, Montreal, QC, Canada.
Martin MistrikInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Petr DzubakInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Juan B De SanctisInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czechia.
Danuta RadziochDepartment of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced metastatic colorectal cancer (CRC) with deficient DNA mismatch repair (MMR-d), or immune-hot CRCs, show significantly improved clinical outcomes compared to MMR-proficient (MMR-p), or immune-cold CRCs. While the prior represents about 5% of all CRCs, the latter represent 95% and are characterized by low immunogenicity. This study investigates bis-diethyldithiocarbamate (CuET), a novel anticancer compound, and its impact on the colorectal cancer tumor microenvironment (TME). CuET is shown to convert immunologically inactive tumors into hotbeds of antitumor immune responses, marked by increased lymphocyte infiltration, heightened cytotoxicity of natural killer (NK) and T cells, and enhanced non-self recognition by lymphocytes. The potent anticancer cytotoxicity and

Indexed as

Antineoplastic AgentsColorectal NeoplasmsCoordination ComplexesCopperDitiocarbNK Cell Lectin-Like Receptor Subfamily KTumor MicroenvironmentAnimalsCell Line, TumorCytotoxicity, ImmunologicFemaleHumansKiller Cells, NaturalMiceSignal TransductionAntineoplastic AgentsCoordination ComplexesCopperDitiocarbKLRK1 protein, humanNK Cell Lectin-Like Receptor Subfamily Kcolorectal cancercopper bis-diethyldithiocarbamatedisulfiramNK cellsNKG2D

Identifiers

PMID40013140
PMCPMC11860975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.